Neurogene Inc NGNE

$25.87 +0.42 (1.65%)

Valuation

Market cap
509,280,000
Revenue TTM
$0
Net income TTM
$-90,350,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
114,000
Avg volume
249,660
Day's range
$25.01 – $26.00
Shares out
20,011,000
Stochastic %K
16%
Beta
1.70
Analysts
Strong Sell
Price target
$79.38

Price

Company profile

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license...

Show more

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
855 508 3568
Website
https://www.neurogene.com
Address
535 W 24th Street, 5th Floor, New York, United States

Latest news

Stocktwits

NVDAMillionaire Oct 5, 6:08 PM
$NGNE Really good write-up that perfectly summarizes NGNE's present situation. So if you want to bring your NGNE knowledge up to date or just discover NGNE, this is required reading. https://everyticker.com/quote/NGNE/analysis/ngne-s-ngn-401-inflection-a-high-stakes-bet-on-rett-syndrome-gene-therapy-nasdaq-ngne
0 replies
STACKD0E Aug 20, 3:43 PM
$NGNE 🙃✨️
0 replies
STACKD0E Aug 11, 12:00 PM
$NGNE 👁
0 replies
focafoca99 Aug 11, 11:42 AM
$NGNE released its June 30, 2026 quarter results via a press release attached to the 8-K.
0 replies
King_of_Bio Jul 28, 10:18 PM
$NGNE Haven't posted much, but bullish here. Wish I got in at 17!
0 replies
ajmrtxl Jul 20, 5:09 PM
$NGNE 's latest squeeze play
0 replies
calibubbles Jul 9, 2:58 PM
$NGNE Holy balls, I had no idea the short interest was that high. This is going to be fun. Definitely not good news for shorts. Great news for science though.
0 replies
TheSealeGroup Jul 9, 2:45 PM
$NGNE is it good news or just shorts covering? Either way could be good positive gains for once.
0 replies